NorthWest Biotherapeutics Inc (NWBO): Thanks for the great link, beartrap12...

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	76
Posts	6475
Boards Moderated	0
Alias Born	05/25/2021

dstock07734

Re: beartrap12 post# 750317

Friday, 02/21/2025 10:45:57 AM

Friday, February 21, 2025 10:45:57 AM

Thanks for the great link, beartrap12

Is it interesting that nearly all the researchers at Institute for Immunology of University Medical Center Mainz have research interests related to dendritic cells after 2020? The CEO of BNTX also has a lab at the Institute. He emptied his webpage and waybackmachine has some descriptions. He must know well about the efficacy of DCVax-L. BNTX is pushing hard for the massive trial in collaboration with NHS over the past a couple of years. We can see the speed that NHS is pushing the trial is impressive.

Tobias Bopp
https://www.unimedizin-mainz.de/immunologie/en/laboratories/bopp-laboratory.html
https://scholar.google.com/scholar?as_ylo=2021&q=Tobias+Bopp+%2B+dendritic+cell&hl=en&as_sdt=0,44

Michael Delacher
https://www.unimedizin-mainz.de/immunologie/en/laboratories/delacher-laboratory.html
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C44&as_ylo=2021&q=Michael+Delacher+%2B++dendritic+cell&btnG=

Charles Imbusch
https://www.unimedizin-mainz.de/immunologie/en/laboratories/imbusch-laboratory.html
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C44&as_ylo=2021&q=Charles+Imbusch+%2B++dendritic+cell&btnG=

Hans Christian Probst
https://www.unimedizin-mainz.de/immunologie/en/laboratories/probst-laboratory.html
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C44&as_ylo=2021&q=Hans+Christian+Probst+%2B++dendritic+cell&btnG=

Markus P Radsak
https://www.unimedizin-mainz.de/immunologie/en/laboratories/radsak-laboratory.html
https://scholar.google.com/scholar?hl=en&as_sdt=0%2C44&as_ylo=2021&q=Markus+Radsak+%2B++dendritic+cell&btnG=

Dr. Ugur Sahin
https://www.unimedizin-mainz.de/immunologie/en/laboratories/sahin-laboratory.html

Research interest

The working group is the orientation of translational research, starting with the scientific idea through application-oriented research to the preclinical development of tailor-made therapies. The focus here is particularly on the development of new therapeutic approaches in the oncological and immunological field (immuntherapies).

A current research programme focuses on the optimization of CAR-T (Chimeric antigen receptor). Here it was recently shown in the Mainz funding program of the CI3 cluster that new TZR-like CARs, TCAR s (TCR-like CAR s), which are based on the coupling with T cell-specific signal molecules of the CD3 complex, have a higher (tumor) antigen sensitivity, i.e. reactivity at low antigen doses, with improved cytoxicity. This can prove to be an effective means of combating refractory or recurrent tumours or a minimal residual disease (MRD). As a direct alternative to classic CARs, 2-chain CARs were developed, which are fusion like classic CARs to CD3z, i.e. are independent of the endogenous CD3 complex, but which have a higher reactivity than classic CARs at moderate antigen doses due to their tandem arrangement of the VH and VL domains. These CARs are to be tested both in the context of tumor antigens and autoimmune antigens. In addition, the efficiency and viability of CAR T cells is to be improved by co-expression of chimeric typical receptors (CCR) and adaptors (CCA) and the modification of the endogenous NKG2D/NKG2DL signal axis.

In addition, AG Sahin has a profound knowledge of flow cytometry and cell sorting (FACSTM) and can offer this technological method as a service provided by the Flow Cytometry Core Facility 911 (FCCF911) to other working groups of the University Medical Center, as well as Johannes Gutenberg University (JGU) and external

https://web.archive.org/web/20221007100313/https://www.unimedizin-mainz.de/immunologie/arbeitsgruppen/ag-sahin.html